Geode Capital Management
CTKB icon

Geode Capital Management’s Cytek Biosciences CTKB Stock Holding History

Geode Capital Management’s Portfolio CTKB Stock Details CTKB Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$13.6M Buy
3,059,573
+225,618
+8% +$963K ﹤0.01% 2375
2026
Q1 		$12.4M Buy
2,833,955
+43,381
+2% +$205K ﹤0.01% 2257
2025
Q4 		$14.1M Buy
2,790,574
+7,125
+0.3% +$33.1K ﹤0.01% 2207
2025
Q3 		$9.66M Buy
2,783,449
+53,856
+2% +$202K ﹤0.01% 2433
2025
Q2 		$9.28M Buy
2,729,593
+42,916
+2% +$143K ﹤0.01% 2416
2025
Q1 		$10.8M Buy
2,686,677
+47,594
+2% +$247K ﹤0.01% 2246
2024
Q4 		$17.1M Sell
2,639,083
-28,921
-1% -$172K ﹤0.01% 2053
2024
Q3 		$14.8M Buy
2,668,004
+89,210
+3% +$506K ﹤0.01% 2146
2024
Q2 		$14.4M Buy
2,578,794
+70,778
+3% +$425K ﹤0.01% 2116
2024
Q1 		$16.8M Buy
2,508,016
+51,481
+2% +$407K ﹤0.01% 2025
2023
Q4 		$22.4M Buy
2,456,535
+102,083
+4% +$642K ﹤0.01% 1839
2023
Q3 		$13M Buy
2,354,452
+292,150
+14% +$2.34M ﹤0.01% 2098
2023
Q2 		$17.6M Buy
2,062,302
+192,832
+10% +$1.73M ﹤0.01% 1939
2023
Q1 		$17.2M Buy
1,869,470
+83,335
+5% +$896K ﹤0.01% 1906
2022
Q4 		$18.2M Buy
1,786,135
+55,467
+3% +$745K ﹤0.01% 1828
2022
Q3 		$25.5M Buy
1,730,668
+585,198
+51% +$7.6M ﹤0.01% 1561
2022
Q2 		$12.3M Buy
1,145,470
+224,330
+24% +$2.23M ﹤0.01% 2110
2022
Q1 		$9.93M Buy
921,140
+566,000
+159% +$7.64M ﹤0.01% 2346
2021
Q4 		$5.79M Buy
355,140
+34,032
+11% +$713K ﹤0.01% 2816
2021
Q3 		$6.87M Buy
+321,108
New +$7.55M ﹤0.01% 2722

Other funds holding CTKB

BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Millennium Management
Millennium Management New York $276B AUM 44.8% 1-Year Est. Return
Boston Partners
Boston Partners Boston, Massachusetts $113B AUM 38.87% 1-Year Est. Return
HA
HHLR Advisors Grand Cayman, Cayman Islands $832M AUM 32.38% 1-Year Est. Return
TCM
Topline Capital Management Santa Monica, California $386M AUM 2.37% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
Dimensional Fund Advisors
Dimensional Fund Advisors Austin, Texas $552B AUM 44.19% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
Goldman Sachs
Goldman Sachs New York $1.15T AUM 47.82% 1-Year Est. Return
RA
Royce & Associates New York $12.4B AUM 64.17% 1-Year Est. Return

Geode Capital Management's CTKB Position: Q2 2026 in Review

Geode Capital Management increased its Cytek Biosciences (CTKB) stake by 8% in Q2 2026, buying an estimated $963K and bringing the position to 3,059,573 shares worth $13.6M. The position accounts for ﹤0.01% of the portfolio, ranked #2375.

Geode Capital Management first reported a position in CTKB in Q3 2021 and has held it in 20 quarters since. The position peaked at $25.5M in Q3 2022. 155 funds tracked by Wall St. Rank hold CTKB as of Q2 2026.

  • Geode Capital Management held 3,059,573 shares of Cytek Biosciences worth $13.6M as of Q2 2026.
  • Geode Capital Management bought 225,618 Cytek Biosciences shares in Q2 2026, an estimated $963K.
  • Cytek Biosciences made up ﹤0.01% of Geode Capital Management's portfolio in Q2 2026, its #2375 holding.
  • Geode Capital Management first reported a position in Cytek Biosciences in Q3 2021 and has held it in 20 quarters since.
  • Geode Capital Management's Cytek Biosciences position peaked at $25.5M in Q3 2022.
  • 155 funds tracked by Wall St. Rank held Cytek Biosciences as of Q2 2026.

Based on Geode Capital Management's 13F filing for Q2 2026, filed 12 Aug 2026.